Quentin Tarantino slams streaming movies, saying that it’s almost like they don’t even exist in the zeitgeist.
While many directors have embraced the streaming world, it’s safe to say that we won’t see Quentin Tarantino making a movie for Netflix anytime soon.
While speaking with Deadline, Quentin Tarantino took aim at streaming services where it feels like the projects exist to feed the content machine instead of being remembered. “I mean, and I’m not picking on anybody, but apparently for Netflix, Ryan Reynolds has made $50 million on this movie and $50 million on that movie and $50 million on the next movie for them,” Tarantino said. “I don’t know what any of those movies are. I’ve never seen them. Have you? I haven’t ever talked to Ryan Reynolds’ agent, but his agent is like, ‘Well, it cost $50 million.’ Well, good for him that he’s making so much money. But those movies don’t exist in the zeitgeist. It’s almost like they don’t even exist.“
Not to continue picking on Ryan Reynolds, but Quentin Tarantino does have a point. Will movies like 6 Underground or Red Notice be remembered as anything other than big-budget misfires?
Quentin Tarantino also spoke about going out on top with his final film, The Movie Critic. “I like the idea of giving it my all for 30 years and then saying, ‘OK, that’s enough.’ And I don’t like working to diminishing returns,” Tarantino said. “And I mean, now is a good time because I mean, what even is a motion picture anyway anymore? Is it just something that they show on Apple? That would be diminishing returns.” That’s part of the reason why Tarantino will likely be doing his last movie with Sony. “I’m probably going to be doing the movie with Sony because they’re the last game in town that is just absolutely, utterly, committed to the theatrical experience,” Tarantino said. “It’s not about feeding their streaming network. They are committed to theatrical experience. They judge success by asses on seats. And they judge success by the movies entering the zeitgeist, not just making a big expensive movie and then putting it on your streaming platform. No one even knows it’s there.“
Speaking of The Movie Critic, Quentin Tarantino recently teased that the film is set in 1977 California and “is based on a guy who really lived, but was never really famous, and he used to write movie reviews for a porno rag.”
Do you agree with Quentin Tarantino about streaming movies? What made-for-streaming movies will continue to be remembered years down the road?
Travis Ansel and DJ Sullivan Will Present Insights on Utilizing Claims-Based Data for Strategic Growth
MGMA Hosts HSG Advisors at 2023 Summit Travis Ansel and DJ Sullivan of HSG Advisors will present on 'How to Utilize Outpatient and Ambulatory Claims-Based Insights for Strategic Growth' at the 2023 MGMA Summit.
LOUISVILLE, Ky., June 6, 2023 (Newswire.com)
-
HSG Advisors, a national healthcare consulting firm, has lined up its CEO Travis Ansel and Chief Strategy Officer DJ Sullivan to speak at the virtual MGMA Summit 2023. HSG Advisors partners with health systems to transform their approach to markets, services, and providers for improved growth, and operational and financial sustainability. The MGMA Summit is a robust learning and networking event developed by Medical Group Management Association (MGMA) for its members. This year's MGMA Summit theme is "Moving Healthcare Forward," and will feature presentations and content from industry leaders on a wide range of medical topics, challenges, and trends.
"HSG Advisors is a long-time partner of MGMA. Its dedication to advocacy and education for medical group practice leaders is the gold standard," says Ansel. "Our leadership team looks forward to any opportunity to support its members and participate in its events, and we're pleased to share our data-driven insights to support healthcare professionals' strategic growth goals."
HSG Advisors' presentation is entitled "How to Utilize Outpatient and Ambulatory Claims-Based Insights for Strategic Growth," and will take place online on Thursday, June 8, from 11-11:50 a.m. ET. The session will feature proprietary claims-based data strategies and tools that provide healthcare leaders with invaluable details on outpatient utilization. Ansel and Sullivan will cover specific examples and case studies of healthcare organizations that are successfully utilizing data to prevent patient leakage, build closer physician alignment, remove access barriers, and optimize practice performance overall.
The MGMA Summit also offers peer networking opportunities even in the virtual environment, and a host of continuing education credit opportunities. HSG Advisors' presentation provides continuing education credits as follows: ACMPE: 1; ACHE: 1; CEU: 1; CME (AAPC*): 1; CPE: 1; PDC: 1; PDU: 1.
HSG Advisors is a national healthcare consulting firm headquartered in Louisville, Kentucky. The practice empowers leaders to build differentiated health system strategies and high-performing employed physician networks by pairing data intelligence with experienced advice. The firm's comprehensive approach to leveraging market facts to inform healthcare strategies allows leaders to understand opportunities and deliver the right care to their communities. For more information about HSG, visit www.HSGAdvisors.com, connect on LinkedIn, email [email protected] or call (502) 814-1180.
Eyenovia is stepping up the capabilities of its facilities and taking advantage of the thriving innovation culture and expertise in Reno, Nevada, and Redwood City, California
NEW YORK, June 6, 2023 (Newswire.com)
-
Eyenovia, Inc. (NASDAQ: EYEN), an ophthalmic technology company commercializing and developing the Optejet® device for use both in connection with its own mydriasis product and product candidates for presbyopia and pediatric progressive myopia as well as out-licensing for additional indications, is proud to announce the expansion of its U.S. manufacturing facilities in Redwood City, California, and Reno, Nevada.
The Bay Area is known for its thriving biotech industry, and in Reno, the medical device and technology sectors are booming in part due to having the largest industrial park in the world, which are some of the driving factors behind Eyenovia's expansion plans.
The Redwood City facility, which was announced operational last year, focuses primarily on Optejet® pharmaceutical manufacturing finishing operations, including drug loading, labeling, and packaging prior to distribution. The new Reno facility will focus on device manufacturing and boasts over 10,000 square feet of space to better serve the growing needs of the company.
"We are pleased to continue executing on our manufacturing strategy by expanding our capabilities in Redwood City and Reno," said Michael Rowe, CEO of Eyenovia. "Our new and upgraded facilities will allow us to continue the development of our existing and future products, better serving our licensees and partners and continuing to advance our mission of improving the delivery of topical ophthalmic therapies."
The U.S. culture of innovation, abundance of investment sources and access to capital markets also contribute to a thriving and innovative environment. According to a 2022 report on the US Biotech Industry:
The biotech industry employed 2.1 million employees across more than 127,000 U.S.-based organizations in 2021.
Despite the overall economy shedding 1.5% of its job base, the bioscience industry in the U.S. has increased employment by 11% since 2018.
The biotech industry's impact on the U.S. economy amounted to roughly $2.9 trillion in 2021.
In a rapidly evolving technological landscape, Eyenovia's expansion of its U.S. manufacturing facilities is a clear sign of the company's commitment to being a technology leader in the medical industry.
For more information on Eyenovia and Optejet®, visit eyenovia.com.
About Eyenovia, Inc.
Eyenovia, Inc. (NASDAQ: EYEN) is a commercial stage ophthalmic pharmaceutical technology company developing a pipeline of microdose array print therapeutics. Eyenovia is currently focused on the commercialization of Mydcombi for mydriasis, as well as the ongoing late-stage development of medications in the Optejet device for presbyopia and myopia progression. For more information, visit Eyenovia.com.
Except for historical information, all the statements, expectations and assumptions contained in this presentation are forward-looking statements. Forward-looking statements include, but are not limited to, statements that express our intentions, beliefs, expectations, strategies, predictions or any other statements relating to our future activities or other future events or conditions, including estimated market opportunities for our product candidates and platform technology. These statements are based on current expectations, estimates and projections about our business based, in part, on assumptions made by management. These statements are not guarantees of future performance and involve risks, uncertainties and assumptions that are difficult to predict. Therefore, actual outcomes and results may, and in some cases are likely to, differ materially from what is expressed or forecasted in the forward-looking statements due to numerous factors discussed from time to time in documents which we file with the U.S. Securities and Exchange Commission.
In addition, such statements could be affected by risks and uncertainties related to, among other things: risks of our clinical trials, including, but not limited to, the costs, design, initiation and enrollment, timing, progress and results of such trials; the timing of, and our ability to submit applications for, obtaining and maintaining regulatory approvals for our product candidates; the potential advantages of our product candidates and platform technology; the rate and degree of market acceptance and clinical utility of our product candidates; our estimates regarding the potential market opportunity for our product candidates; reliance on third parties to develop and commercialize our product candidates; the ability of us and our partners to timely develop, implement and maintain manufacturing, commercialization and marketing capabilities and strategies for our product candidates; intellectual property risks; changes in legal, regulatory, legislative and geopolitical environments in the markets in which we operate and the impact of these changes on our ability to obtain regulatory approval for our products; and our competitive position.
Any forward-looking statements speak only as of the date on which they are made, and except as may be required under applicable securities laws, Eyenovia does not undertake any obligation to update any forward-looking statements.
The acquisition of Rebate Insight provides SpendMend with advanced rebate management automation tools to help healthcare organizations maximize rebate earnings and reduce supply costs.
GRAND RAPIDS, Mich., June 6, 2023 (Newswire.com)
-
SpendMend, a leading provider of solutions to optimize the cost-cycle for the healthcare industry, today announced the successful completion of its purchase of Rebate Insight, a software solution provider that streamlines the management and optimization of rebates for healthcare organizations.
Rebate management is an essential part of reducing the overall cost of supplies, leading to better operating margins and improved cash flow for healthcare organizations. Rebate Insight has developed a best-in-class solution to help healthcare organizations optimize their rebate potential and reduce supply costs by automating the data organization and analysis. The software provides real-time compliance insights, forecasting tools, and powerful data analytics to help hospitals and healthcare systems maximize their rebate earnings.
Community Memorial Health System's Senior Vice President and COO, Adam Thunell, praised Rebate Insight for providing real-time visibility into rebate opportunities. "Through the automated dashboards and forecasting functionality, our supply chain team has real-time data, allowing us to be more strategic in our decision-making and increase our rebates," said Thunell.
Tony Garcia, Founder & CEO of Rebate Insight, expressed high optimism about the acquisition, "Joining SpendMend will provide us a great opportunity to serve a larger portion of the healthcare industry. Our teams share a common goal of driving cost-savings and operational efficiencies for our clients, and together, we will be able to deliver even greater value to the healthcare organizations we serve."
Co-founder & COO of Rebate Insight, Jonas Langvad, also commented, stating, "We are eager to collaborate with SpendMend to provide top-tier cost-savings and support to hospitals and health systems across the country."
SpendMend CEO Dan Geelhoed offered, "We're excited to add Rebate Insight to our portfolio of solutions that help healthcare organizations improve their cost-cycle. Rebate Insight is a valuable tool to illuminate dark data and drive more visibility into the rebate management process in healthcare. This acquisition is part of our ongoing commitment to providing innovative cost-savings solutions for our clients."
Rebate Insight's clients can expect no interruption of service as a result of the acquisition. Garcia and Langvad will continue to manage day-to-day operations for the new division from Rebate Insight's headquarters in Ventura, California.
About SpendMend
SpendMend is a leading provider of tech-enabled, cost-savings solutions in the healthcare industry. Combining the use of data, proprietary technology, and rigorous analytics with its healthcare focus and expertise, SpendMend partners with healthcare networks to expose the dark data to improve and optimize their costs in meaningful and collaborative ways. SpendMend's mission is to help its clients improve their patient care through innovative cost-savings solutions.
About Rebate Insight
Rebate Insight is a Los Angeles-based software provider that streamlines the management and optimization of rebates for healthcare organizations. The software provides real-time compliance insights, forecasting tools, and powerful data analytics to help healthcare organizations maximize their rebate earnings.
Contact Information:
Kylee Savage
Marketing Manager [email protected]
616-257-8331
TAMPA, Fla., June 6, 2023 (Newswire.com)
-
Oncology informatics company Inspirata recently reached out to several hundred customer sites with an invitation to participate in a Customer Satisfaction survey. The company collected more than 60 responses, representing healthcare organizations varying in size, geography, and the Inspirata product they have been using.
The survey results reveal a strikingly high percentage of Inspirata customers (92%) who express strong overall satisfaction. Putting this in terms of a well-understood and standardized metric, the company's net promoter score (NPS) stands at 56, which places Inspirata in the 100th percentile of the software industry, according to benchmarks on Delighted.com (a website run by Qualtrics, an industry-leader in market research technology).
"We are delighted to see such a level of enthusiasm among our customers as we recognize how high an NPS of 56 compares to mainstay brands in healthcare technology. According to recent publicly available data, IQVIA has an NPS of 28, while Epic's NPS is 30. It is very exciting to see Inspirata comparing favorably against some of the largest players in the industry," said Emil Mladenov, VP of Marketing and Strategic Partnerships at Inspirata.
The high ratings can be attributed to customers' strong appreciation of both Inspirata's products and the support the Inspirata team is providing when needed.
On the product side, customers report their teams are experiencing average productivity gains between 45% and 50% from using Inspirata products. Nine out of 10 customers are satisfied with product stability.
"Inspirata's products are deeply rooted in AI and NLP technology that the company has been developing in collaboration with the NCI's SEER program and hundreds of healthcare institutions over two decades. Many other vendors offering AI or NLP still struggle with accuracy and reliability. This is why we are extremely proud to see less than 2% of our customers expressing concerns with the accuracy of our technology. Knowing that our existing customers are getting the results they expect gives us strong confidence when we speak to new customers," said Jesse Turner, VP of Sales at Inspirata.
"While very much pleased to see these results, my team and I are not surprised that customers recognize the accuracy and stability of our technology," said George Cernile, VP of AI and NLP Technology at Inspirata. "These results align closely with the Quality Control (QC) studies that we periodically do with our customers. For example, since the beginning of 2020, over more than 40 QC studies, we see sensitivity of 99% and specificity of 98%, with very little variation - only within several percentage points - across the various sites where our products are installed. That demonstrates successfully scaling the technology across different systems and physicians, which can be a significant challenge for most AI and NLP solutions."
On the customer support side, 96% of customers who had needed help are satisfied with the services provided by the Inspirata team. This is further evidenced by extremely positive quotes provided by survey respondents, such as the following two examples:
"I love the level of customer service that Inspirata provides." - A verbatim quote from a user at a Georgia-based medical center.
"The customer service has been top notch every time I have needed to contact them." - a verbatim quote from a user at a university hospital in New Jersey.
"We strive for excellence in every single interaction we have with our customers," said Laure Tessier-Delivuk, VP of Operations at Inspirata. "What we see in the Customer Satisfaction survey correlates very well with the feedback we collect after closing every single support ticket. Over the past two years, we've maintained a 4.9 out of 5 for overall level of satisfaction related to how we handle customer requests."
Inspirata has also leveraged the data from the Customer Satisfaction survey to learn about potential product areas for improvement or identify unaddressed customer needs. The company is confident that drawing up action plans to incorporate as many of customers' suggestions as possible would make the next generation of products even more impactful and easier to use.
"The survey gives us access to very interesting data. The good news is that for every feature request made in the survey, we have already managed to add a user story to our product roadmap. Many of these new features or functionalities are on track to be delivered before the end of the year," said Tim Masters, Director of Product Management and Design.
To learn more about the company, its portfolio of solutions, the decades of work dedicated to refining its AI and NLP technology for clinical data use cases, and the team behind all this, please visit Inspirata.com.
About Inspirata
Inspirata, Inc. helps patients fighting cancer—and the clinicians they trust—to make every moment matter. We are an oncology informatics company that offers several innovative software solutions leveraging scalable AI and NLP in the clinical trial and cancer registry spaces. Refined over two decades in collaboration with the National Cancer Institute (NCI) and used by hundreds of healthcare institutions globally, our proprietary NLP engine is at the heart of Trial Navigator, our growing suite of fully automated clinical trial matching solutions, and E-Path Plus, our industry-leading cancer registry reporting and data abstraction solution.
Contact Information:
Emil Mladenov
Vice President of Marketing and Strategic Partnerships [email protected]
+1 813-570-8914
Protecting digital footprint and social media accounts in the digital age
NEW YORK, June 6, 2023 (Newswire.com)
-
A developer of digital asset management solutions, including password managers and power of attorney, Legacy Suite now offers a social media legacy package for anyone wanting to protect their online identity, deal with legal considerations after death, and provide closure for loved ones in a comprehensive estate planning for protection against social media accounts.
"In today's digital age, social media has become an integral part of our lives, shaping how we connect with others and share our experiences," Sean Foote, CEO of Legacy Suite, said. "As we create and curate our digital presence, a 'social media legacy' emerges—a lasting record of our thoughts, emotions, and moments captured online. But what happens to this social legacy when we are no longer here?"
A social media legacy program for social media accounts protects an online identity and ensures a digital footprint that aligns with personal values and wishes. With Legacy Suite, data, digital vaults, and passwords can be managed, stored, and assigned to digital executors, beneficiaries, and trusted contacts.
"A legacy plan helps safeguard your online persona from potential misuses, such as identity theft or unauthorized access," Foote said. "By designating a digital executor or legacy contact, you can ensure that your social media accounts are handled according to your wishes."
Since social media accounts contain cherished memories and personal moments, the legacy suite can provide closure for loved ones. "By creating a legacy plan, you can offer your loved ones a chance to access, archive, or memorialize your digital presence, helping them find closure and solace during their time of grief," Foote said.
More than ever, it is important to restrict digital footprints to maintain control after death. "A social media legacy plan allows you to decide the fate of your online presence, whether it involves deleting your accounts, memorializing them, or handing over control to a trusted individual," Foote said.
A well-crafted plan can prevent tricky situations concerning content by outlining how accounts should be managed or deactivated. "Without a legacy plan, your social media profiles may continue to appear in search results, friend suggestions, or birthday reminders, causing distress for your friends and family," Foote said.
There are legal considerations with digital assets being recognized as part of one's estate. A social media legacy plan can help streamline the legal processes involved in settling affairs.
For more information on safeguarding your future, please visit www.legacysuite.com.
About Legacy Suite
Legacy Suite is a complete end-to-end solution providing first-class digital estate planning support, including wallet monitoring and crypto wallets. Legacy Suite is a secure solution for crypto self-custody and password management, which allows you to hold your own keys, set up directives, assign executors, and have peace of mind knowing that your digital assets will safely transfer to your next of kin.
Communication is the cornerstone of quality healthcare, making effective communication critical to quality outcomes for patients with communication barriers.
Never miss a word! VidaTalk is the most comprehensive hospital-based speech and language support solution available. Designed and validated by patients and their providers, VidaTalk is evidence-based and proven to drive outcomes improvement.
ANN ARBOR, Mich., June 6, 2023 (Newswire.com)
-
Released today, VidaTalk expands its impact, further empowering the most vulnerable patients throughout the healthcare system with its new talk-to-text feature. By providing seamless communication between patients who are hard of hearing and their healthcare professionals, VidaTalk ensures these patients are able to comprehend medical information accurately and effectively.
"Empowering autonomy for patients with speech and language barriers is our core mission," states Dr. Patak, CEO of Vidatak, LLC. "Our Program is unique in that our active, ongoing engagement with our clients allow us to capture best practices from world class healthcare systems across the country and share these with our clients to help optimize their workflow processes and provider education in a way that achieves the patient empowerment and autonomy they envision was possible."
VidaTalk is not just a solution; it is a change in practice.
To use the talk-to-text feature, simply tap on the keyboard tab, then activate the microphone by tapping on the microphone symbol. All transcription is performed in real time. No data is stored.
Lisa Spencer, Vidatak's Chief Experience Officer shares her insight explaining, "VidaTalk promotes equitable and patient-centered healthcare experiences for patients who rely on sign language interpreters, and even more importantly, for those patients who lost their hearing and haven't learned signed language."
Talk-to-text has transformed the way healthcare providers engage with their patients who are hard of hearing, improving efficiency, accuracy, mutual understanding and comprehension of care, fostering independence and enhancing relationships.
Healthcare institutions that embrace and implement such advancements to ensure inclusive and accessible care for their most vulnerable patients - including those with speech, hearing and language barriers - model health equity and are positioned to report the best outcomes and be the most profitable.
Contact Information:
Lance Patak
CEO [email protected]
(323) 697-9906
Lisa Spencer
Chief Experience Officer [email protected]
(425) 247-4007 Related Images
Never miss a word!
VidaTalk is the most comprehensive hospital-based speech and language support solution available. Designed and validated by patients and their providers, VidaTalk is evidence-based and proven to drive outcomes improvement.
Make it easier to achieve better
The cost of co-morbidities from ineffective communication will exceed your DRG reimbursement. Accurate communication is necessary to diagnose and treat patients' symptoms. Stop making your patients play charades.
VidaTalk's Extensive Value Proposition
VidaTalk is not just a solution, it is a change in practice. Take advantage of Vidatak's free Program and ongoing consultation to bring best practices to the bedside at your institution today!
Mark Hamill would be fine if they recast Luke Skywalker with an age-appropriate actor instead of using de-aging/deep-fake.
Before Mark Hamill made his return as Luke Skywalker in Star Wars: The Force Awakens, the last time we saw the character was in Star Wars: Return of the Jedi. Given the decades of history that took place between those two movies, it’s only natural that Lucasfilm would want to explore it. We’ve seen bits and pieces of that story play out in The Mandalorian and The Book of Boba Fett with a digital/deep-fake Luke Skywalker, but Mark Hamill told Esquire that it would be fine if they just recast the character with someone age-appropriate.
“People say, ‘Oh, now you’re going to be able to do a whole series of Luke post-Return of the Jedi.’ I said, ‘I don’t think so,’” Mark Hamill said. “First of all, they don’t need to tell those stories, but if they do, they could get an age-appropriate actor.” It would certainly cut down on costs, as Hamill added that the digital Luke Skywalker “can’t be cheap.“
When Mark Hamill read the script for Star Wars: The Last Jedi, he thought, “Ok, well, that’s it for me.” He then began the process of “disengaging from something that’s been a part of your life.” Of course, he wound up returning as a Force Ghost in Star Wars: The Rise of Skywalker, but he hadn’t anticipated playing the role again until The Mandalorian came calling. With one of the new Star Wars movies taking place 15 years after The Rise of Skywalker as Rey (Daisy Ridley) attempts to rebuild the Jedi Order, it’s possible that Mark Hamill could return as Luke Skywalker once again, but Hamill isn’t about to confirm anything. “One thing you learn working for Lucasfilm: everything is confidential,” Hamill said. “Everything is confidential. So, if I were involved, I wouldn’t be able to tell you. And if I were not involved, I wouldn’t be able to tell you. So, I don’t know. We’ll all find out together, I guess.“
Mark Hamill can currently be seen starring alongside Bert Kreischer in The Machine. Check out a review from our own Alex Maidy right here.
How do you feel about Luke Skywalker being recast for post-Return of the Jedi stories instead of using de-aging/deep-fake?
HBO’s Head of Drama Francesca Orsi says that Euphoria season 3 may not debut until 2025 as result of WGA strike.
The second season of HBO’s Euphoria concluded more than a year ago, but fans will have to wait longer than expected for season 3.
HBO’s Head of Drama Francesca Orsi told Deadline that Euphoria season 3 is one of many shows impacted by the WGA strike and may not debut until 2025. “Euphoria is one of those that we had begun writing in tandem with post-production on Idol but at this point, we don’t have countless scripts,” Orsi said. “We can’t start shooting, so the delivery of that show — ideally in 2025 — will be determined on when we can pick back up with Sam [Levinson], who at this point is all pencils down and just finishing posts on Idol.“
Euphoria is far from the only HBO series affected by the strike, although Orsi says that it’s still “too early to tell” exactly how previously announced scheduling plans will change. “We were looking at The Last Of Us for some time in 2025,” Orsi said. “And The White Lotus was ideally looking to go in 2024 but there’s some question about timing of the strike.” She continued: “While everything at this moment is pencils down, I’m hopeful that we can come to terms sooner than later. Otherwise we will have to assess what is the end of the 24 schedule, what are the shows that are going to be delivered for 2025. At this point, those shows that I’m looking to air wouldn’t necessarily be ready if this strike last six to nine months. So yes, that’s a big question for us, but I think we’ll cross that road once we come to it.“
Euphoria follows a group of high school students as they navigate drugs, sex, identity, trauma, social media, love and friendship. The show has become one of HBO’s most-watched series. Sam Levinson’s next series is The Idol, a drama which follows an aspiring pop idol (Lily-Rose Depp) who, after having a nervous breakdown that causes her last tour to be canceled, resolves to reclaim her title as the sexiest pop star in America and begins a complex relationship with Tedros (Abel Tesfaye), a self-help guru and the head of a contemporary cult. The series is said to rival Euphoria when it comes to shocking content, so I’d imagine that plenty will be turning out to view the series when it debuts on HBO on June 4th.
BEVERLY HILLS, Calif., June 5, 2023 (Newswire.com)
-
Michelle's traumatic miscarriage and failed IVF treatment in Hong Kong inadvertently prepared her for leading IMA ART Fertility Beverly Hills. The Hong Kong experience honed Michelle's listening skills and to speak to clients with compassion and empathy.
Michelle and her husband were among the estimated 15% of couples who experience infertility. For several years, the couple tried to conceive naturally, ultimately turning to a disappointing Hong Kong IVF cycle. During their journey to parenthood, Michelle suffered a miscarriage, loss of a frozen embryo at a clinic in Hong Kong, and a failed embryo implantation. Her first-hand experience in Hong Kong demonstrated the decisive difference in reproductive healthcare standards between Hong Kong and California.
After the miscarriage, Michelle courageously turned adversity to strength, channelling her deep feelings of personal loss into connecting with, and helping others, through their own IVF and Surrogacy journeys. After arriving in Beverly Hills, Michelle sought the help of well known & highly respected Dr Thaïs Aliabadi. Within a few months of the first consultation, Michelle tested positive for pregnancy.
Dr Aliabadi provided experienced, skilled and compassionate obstetric care during Michelle's pregnancy and delivery. Miranda Ripper, Certified Registered Nurse Specialist in Labor & Delivery - a private nurse working along side Dr. Aliabadi - met Michelle and her husband at check-in and remained by her side through labor and delivery. Miranda's 25 years of clinical expertise in nursing, helped educate, guide, and support Michelle through labor and Dylan's birth.
The CDC's definition of infertility is not being able to get pregnant after 12 months of unprotected sex. Because fertility in women is known to decline steadily with age, some providers evaluate and treat women aged 35 years or older after 6 months of unprotected sex. In the United States, among heterosexual women aged 15 to 49 years with no prior births, about 1 in 5 (19%) are unable to get pregnant after one year of trying (infertility). Also, about 1 in 4 (26%) women in this group have difficulty getting pregnant or carrying a pregnancy to term (impaired fecundity).
IMA ART understands the process preceding the decision to ultimately seek professional fertility assistance needs time and patience. Michelle knows how stressful & physically draining infertility treatments can be. Patients receive personal treatment protocols addressing their unique needs. The company provides their clients with access to a privately curated network of world-class fertility specialists, reproductive lawyers, psychological assistance and exceptional concierge services. California IVF success rates make it the fertility capital of the world.
About the Company: IMA ART is a high-value bespoke professional advisory service providing luxury fertility & surrogacy concierge and solutions in Beverly Hills. The company offers an exclusive suite of discreet fertility options geared towards busy high net worth individuals. Learn more at www.imaartfertility.com.
Contact Information:
Ron Sonnenberg
Co-Founder [email protected]
(424)-284-1408
